While early GLP1 drugs focused primarily on diabetes, newer agents, such as tirzepatidebased therapies, have gained traction in treating obesity, raising efficacy expectations and increasing competitive dynamics

Safety Considerations and Contraindications Who Should Avoid AOD 9604 Contraindications : Pregnancy or breastfeeding Active cancer diagnosis Severe cardiovascular disease Uncontrolled diabetes Children and adolescents under 18 Potential Drug Interactions AOD 9604 may interact with: Insulin and diabetes medications Growth hormone therapies Thyroid medications Stimulant-based weight loss drugs Medical Supervision Requirements Consult healthcare providers before starting AOD 9604 if you have: Metabolic disorders Cardiovascular conditions Diabetes or pre-diabetes History of eating disorders Current prescription medications Our Clinics Experience with AOD 9604 Dosing Through extensive clinical experience with AOD 9604 protocols, weve observed optimal fat loss results with 300-400 mcg daily dosing
Intracellular micronutrients refer to the vitamins and minerals present within the bodys cells
Research protocols measuring body composition or urinary methylnicotinamide excretion usually run 816 weeks to capture meaningful shifts
Andre, P., Nannizzi-Alaimo, L., Prasad, S